TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01265576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
Study: NCT04052867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: An equivalent volume of normal saline is given
Study: NCT01512381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of CRT device
Description: RV lead of CRT system is implanted into the middle part of interventricular septum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of conventional VVI(R) pacemaker
Description: RV lead is implanted into the middle part of interventricular septum
Study: NCT02335970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group
Description: After 1 week~* Chest expansions~* Static thoracic extension in prone~* Lateral flexion of the spine in standing~* Bilateral shoulder flexion~* Shoulder external rotation of shoulders~* Rotation of the thoracic spine in sitting~* Static back extensor strength in prone~After 1 month~* Thoracic extension, rotation and flexion abduction~* Hand in neck and in back~* Bilateral active flexion abduction~* Strength training of leg muscles~* Static back extensor strength~After 2 months~* Strength training of legs and back muscles~* Push-ups against a wall~* Thoracic extension in sitting and standing~* Thoracic rotation in lying~* Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise
Study: NCT00900159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: eszopiclone
Description: 3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
Study: NCT02851589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCAR-019 (anti-CD19 CAR-T cells)
Study: NCT04373759

Intervention type: OTHER
Intervention: Cardiopulmonary resuscitation
Description: Cardiopulmonary resuscitation

Intervention type: OTHER
Intervention: Modified Rankin score
Description: 0 - no symptoms at all~1. - no significant disability despite symptoms; able to carry out all usual duties and activities~2. - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~3. - Moderate disability; requiring some help, but able to walk without assistance~4. - Moderately severe disability; unable to walk and attend to bodily needs without assistance~5. - Severe disability; bedridden, incontinent and requiring constant nursing care and attention~6. - Dead

Intervention type: OTHER
Intervention: Modified Rankin score
Description: 0 - no symptoms at all~1. - no significant disability despite symptoms; able to carry out all usual duties and activities~2. - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~3. - Moderate disability; requiring some help, but able to walk without assistance~4. - Moderately severe disability; unable to walk and attend to bodily needs without assistance~5. - Severe disability; bedridden, incontinent and requiring constant nursing care and attention~6. - Dead

Intervention type: OTHER
Intervention: Modified Rankin score
Description: 0 - no symptoms at all~1. - no significant disability despite symptoms; able to carry out all usual duties and activities~2. - Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance~3. - Moderate disability; requiring some help, but able to walk without assistance~4. - Moderately severe disability; unable to walk and attend to bodily needs without assistance~5. - Severe disability; bedridden, incontinent and requiring constant nursing care and attention~6. - Dead
Study: NCT03529955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
Study: NCT02460848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient therapeutic program, counseling and cash transfer
Description: Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient therapeutic program and counseling
Study: NCT04901000

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Carotid endarterectomy prior to CABG operations either under Local Anaesthetic or under General Anaesthetic.

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: Carotid endarterectomy prior to CABG operations either under Local Anaesthetic or under General Anaesthetic.
Study: NCT03086356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Days 1-4 and Day 8-11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Description: Day 11
Study: NCT03303638

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multi-sensory Environment
Description: Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
Study: NCT03322514

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: Inulin
Study: NCT02992405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS Resilience Enhancement Program
Description: Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist (No Study Treatment)
Description: Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
Study: NCT01842958

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann Bone Level Implants, 4.1 mm implant diameter
Description: Straumann Bone Level Implants, 4.1 mm implant diameter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann Bone Level Implants, 3.3 mm implant diameter
Description: Straumann Bone Level Implants, 3.3 mm implant diameter
Study: NCT02474290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study: NCT03476187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: µCor
Description: Monitor with µCor
Study: NCT04093570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 film-coated, immediate-release FDC tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 film-coated, immediate-release FDC tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 film-coated, immediate-release FDC tablets
Study: NCT00747370

Intervention type: PROCEDURE
Group type: OTHER
Intervention: movement of midurethra, bladder neck, cervix and rectum

Intervention type: PROCEDURE
Group type: OTHER
Intervention: movement of midurethra, bladder neck, cervix and rectum

Intervention type: PROCEDURE
Group type: OTHER
Intervention: movement of midurethra, bladder neck, cervix and rectum
Study: NCT03937128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training
Description: Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Services as usual
Description: Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
Study: NCT03715478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2857916 with Pomalidomide and Dexamethasone
Description: Recommended phase 2 dose (RP2D) of GSK2857916 determined by the phase 1 portion of study will be administered in combination with pomalidomide (approved dose and schedule) and dexamethasone until progression of disease.
Study: NCT03556839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Carboplatin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous Infusion
Study: NCT01105923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAPLE
Description: MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
Study: NCT02122705

Intervention type: DEVICE
Intervention: VPIA remifentanil
Description: Vital signs controlled patient assisted intravenous analgesia using remifentanil
Study: NCT05712213

Intervention type: PROCEDURE
Intervention: Intraperitoneal onlay mesh reinforcement with defect closure before placement of mesh (pIPOM)
Description: The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. The laparoscopic closure of the hernia defect was performed with non-reabsorbable detached stitches of prolene 1/0 suture at a distance of 1.5 cm from stich to stich using a Reverdin' needle. The final fixation of the mesh took place with a non-resorbable tacks.

Intervention type: PROCEDURE
Intervention: Standard intraperitoneal onlay mesh repair (sIPOM)
Description: The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. In sIPOM, the defect was not closed. The final fixation of the mesh took place with a non-resorbable tacks.
Study: NCT04251793

Intervention type: OTHER
Intervention: Observation
Description: Soft tissue implant measurements and radiographs

Intervention type: OTHER
Intervention: Observation
Description: Soft tissue implant measurements and radiographs
Study: NCT02002455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT, PET/MRI, mpMRI
Description: FACBC dose 370 megabecquerel (MBq)
Study: NCT03306082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image-Guided Cochlear Implant Programming
Description: Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
Study: NCT04035434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX110
Description: CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
Study: NCT05119387

Intervention type: OTHER
Intervention: Observation
Description: Observation of genetic characteristics
Study: NCT03119350

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Training
Description: Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate.
Study: NCT02259192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED-EL Maestro Cochlear Implant
Description: cochlear implant
Study: NCT00049166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study: NCT06251752

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-rays: load bearing inferior limbs, lateral knee, axial patella
Description: X-rays at 5 years follow-up minimum

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-rays: load bearing inferior limbs, lateral knee, axial patella
Description: X-rays at 5 years follow-up minimum
Study: NCT05125575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)
Description: One tablet of the Test (T) product was administered orally with 240 mL of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 1000 mg Prolonged Release Tablets
Description: One tablet of the Reference (R) product was administered orally with 240 mL of water.
Study: NCT02701127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral niacinamide, 1 gram daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral niacinamide, 3 gram daily
Study: NCT00049166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT00916890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
Study: NCT00049166

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo intensity modulated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo intensity modulated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00916890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
Study: NCT01983020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00049166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02217410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Tac)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Study: NCT01909466

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole, OPC-14597
Description: 5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole, OPC-14597
Description: 5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
Study: NCT02217410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (CS)
Study: NCT02775890

Intervention type: BEHAVIORAL
Intervention: Eating wild game shot with lead bullets
Description: Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (\>85 grams).
Study: NCT04693065

Intervention type: OTHER
Intervention: ponseti
Description: Standard of care, treatment by ponseti method
Study: NCT02217410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-IL2 Induction

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anti-IL2 Induction
Study: NCT02907528

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bone
Description: Furcation defect regenerated with bone graft material
Study: NCT02780557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent Reading Intervention
Description: Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Book Provision Control
Description: Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
Study: NCT03931096

Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: Self and proxy PedsQL 4.0 questionnaires.

Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: Self and proxy PedsQL 4.0 questionnaires.
Study: NCT04050397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive supervised weight training
Description: 12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lecture
Description: Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.